S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
NASDAQ:ORTX

Orchard Therapeutics Stock Forecast, Price & News

$1.89
-0.15 (-7.35 %)
(As of 10/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.85
$2.03
50-Day Range
$2.02
$3.09
52-Week Range
$1.85
$9.08
Volume1.67 million shs
Average Volume1.19 million shs
Market Capitalization$236.95 million
P/E RatioN/A
Dividend YieldN/A
Beta1.12
30 days | 90 days | 365 days | Advanced Chart
Receive ORTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Orchard Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Orchard Therapeutics logo

About Orchard Therapeutics

Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ORTX
Employees
2,020
Year Founded
N/A

Sales & Book Value

Annual Sales
$2.60 million
Book Value
$1.82 per share

Profitability

Net Income
$-151.98 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$236.95 million
Next Earnings Date
11/2/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.96 out of 5 stars

Medical Sector

630th out of 1,359 stocks

Biological Products, Except Diagnostic Industry

102nd out of 196 stocks

Analyst Opinion: 3.4Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Orchard Therapeutics (NASDAQ:ORTX) Frequently Asked Questions

Is Orchard Therapeutics a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Orchard Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Orchard Therapeutics stock.
View analyst ratings for Orchard Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Orchard Therapeutics?

Wall Street analysts have given Orchard Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Orchard Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Orchard Therapeutics' next earnings date?

Orchard Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 2nd 2021.
View our earnings forecast for Orchard Therapeutics
.

How were Orchard Therapeutics' earnings last quarter?

Orchard Therapeutics plc (NASDAQ:ORTX) announced its quarterly earnings results on Wednesday, August, 4th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.03.
View Orchard Therapeutics' earnings history
.

How has Orchard Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Orchard Therapeutics' stock was trading at $9.08 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ORTX shares have decreased by 79.2% and is now trading at $1.89.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ORTX?

4 Wall Street analysts have issued 12 month price targets for Orchard Therapeutics' stock. Their forecasts range from $12.00 to $17.00. On average, they anticipate Orchard Therapeutics' stock price to reach $13.75 in the next twelve months. This suggests a possible upside of 627.5% from the stock's current price.
View analysts' price targets for Orchard Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Orchard Therapeutics' key executives?

Orchard Therapeutics' management team includes the following people:
  • Bobby Gaspar, Chief Executive Officer & Executive Director
  • Frank E. Thomas, President, COO, CFO & Chief Accounting Officer
  • Andrea Spezzi, Chief Medical Officer
  • Ran Zheng, Chief Technical Officer
  • Nicoletta Loggia, Chief Technical Officer

What other stocks do shareholders of Orchard Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Orchard Therapeutics investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP), Entasis Therapeutics (ETTX), (NGM), Selecta Biosciences (SELB) and VBI Vaccines (VBIV).

When did Orchard Therapeutics IPO?

(ORTX) raised $200 million in an IPO on Wednesday, October 31st 2018. The company issued 13,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Orchard Therapeutics' stock symbol?

Orchard Therapeutics trades on the NASDAQ under the ticker symbol "ORTX."

How do I buy shares of Orchard Therapeutics?

Shares of ORTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Orchard Therapeutics' stock price today?

One share of ORTX stock can currently be purchased for approximately $1.89.

How much money does Orchard Therapeutics make?

Orchard Therapeutics has a market capitalization of $236.95 million and generates $2.60 million in revenue each year. The company earns $-151.98 million in net income (profit) each year or ($1.53) on an earnings per share basis.

How many employees does Orchard Therapeutics have?

Orchard Therapeutics employs 2,020 workers across the globe.

What is Orchard Therapeutics' official website?

The official website for Orchard Therapeutics is www.orchard-tx.com.

Where are Orchard Therapeutics' headquarters?

Orchard Therapeutics is headquartered at 108 CANNON STREET, LONDON X0, EC4N 6EU.

How can I contact Orchard Therapeutics?

Orchard Therapeutics' mailing address is 108 CANNON STREET, LONDON X0, EC4N 6EU. The company can be reached via phone at 442038088286.


This page was last updated on 10/24/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.